DixonLabNotts's profile picture. Developing novel intracellular therapeutics using gene technologies and drugs | RMCT Division, Pharmacy, BDI, University of Nottingham

Dixon Lab | UoN

@DixonLabNotts

Developing novel intracellular therapeutics using gene technologies and drugs | RMCT Division, Pharmacy, BDI, University of Nottingham

Dixon Lab | UoN reposted

Cobra Biologics to manufacture plasmids for Phase I clinical trial COVID-19 vaccine ddw-online.com/product-news/p… #COVID19

DDWJournal's tweet image. Cobra Biologics to manufacture plasmids for Phase I clinical trial COVID-19 vaccine

ddw-online.com/product-news/p…

#COVID19

Dixon Lab | UoN reposted

.@CobraBiologics, a CDMO and part of Cognate BioServices, and .@scancellpharma have entered into a collaboration for Cobra to manufacture Scancell’s #COVID19 vaccine. Learn more: ow.ly/wYjD50BHYN0

GENbio's tweet image. .@CobraBiologics, a CDMO and part of Cognate BioServices, and .@scancellpharma have entered into a collaboration for Cobra to manufacture Scancell’s #COVID19 vaccine. Learn more: ow.ly/wYjD50BHYN0

Dixon Lab | UoN reposted

📢@CobraBiologics and @scancellpharma today announced that they have entered into a collaboration for Cobra to manufacture Scancell’s COVID-19 vaccine.💉👇

TODAY: Cobra Biologics selected to manufacture plasmids for clinical trial of @scancellpharma’s COVID-19 vaccine Read the press release in full >>> cobrabio.com/news/cobra-to-…



Dixon Lab | UoN reposted

This is fantastic news - collaboration between Scancell, @UniofNottingham & @TrentUni for #COVID19 vaccine to clinical trials Delighted some of this stellar science will be done by researchers in the Biodiscovery Institute Story at nottingham.ac.uk/news/funding-f… #WeAreUoN

Scientists @UniofNottingham and @TrentUni are to begin clinical trials for a DNA vaccine to prevent #COVID19 -Working with @scancellpharma to adapt its existing cancer vaccine platform for the development of a new #vaccine #WeareUon #Unistogether #UoNNews ow.ly/gMoR50BavjN

UoNPressOffice's tweet image. Scientists @UniofNottingham and @TrentUni are to begin clinical trials for a DNA vaccine to prevent #COVID19 -Working with @scancellpharma  to adapt its existing cancer vaccine platform for the development of a new #vaccine #WeareUon #Unistogether #UoNNews ow.ly/gMoR50BavjN


Dixon Lab | UoN reposted

🔴 News from our #COVID19 Live blog: 👉 UK awards £4M to two early stage COVID-19 vaccine projects from @VaccitechLtd and @scancellpharma. Read more ➡️ bit.ly/liveblog19

scibus's tweet image. 🔴 News from our #COVID19 Live blog:

👉 UK awards £4M to two early stage COVID-19 vaccine projects from @VaccitechLtd and @scancellpharma.

Read more ➡️ bit.ly/liveblog19

Dixon Lab | UoN reposted

Scientists @UniofNottingham and @TrentUni are to begin clinical trials for a DNA vaccine to prevent #COVID19 -Working with @scancellpharma to adapt its existing cancer vaccine platform for the development of a new #vaccine #WeareUon #Unistogether #UoNNews ow.ly/gMoR50BavjN

UoNPressOffice's tweet image. Scientists @UniofNottingham and @TrentUni are to begin clinical trials for a DNA vaccine to prevent #COVID19 -Working with @scancellpharma  to adapt its existing cancer vaccine platform for the development of a new #vaccine #WeareUon #Unistogether #UoNNews ow.ly/gMoR50BavjN

Dixon Lab | UoN reposted

@OpenOrphan @scancellpharma #ReNeuron @Parsotix. A brilliant evening of biotech and potential life savers from 6pm tonight at the @proactive_UK virtual forum. Join them. Join us. Join me


Dixon Lab | UoN reposted

$SCLP Scancell Holdings consortium gets government backing for Covid trial tinyurl.com/y3dsvhh3 via @proactive_UK @scancellpharma #SCLP


Dixon Lab | UoN reposted

Fantastic to see @scancellpharma receive @innovateuk funding to kick start clinical development of a COVID-19 #vaccine.💉

Scancell-led consortium receives funding from @innovateuk and @UKRI_News for #COVID19 vaccine development @JonathanKBall @DixonLabNotts @JamesEdDixon @UniofNottingham @trentiuni



Dixon Lab | UoN reposted

An RNA vaccine candidate for SARS-CoV-2, BNT162b1, is shown to induce a robust immune response in healthy adults aged 18–55 years in an interim report of a phase 1/2 clinical trial published in Nature. go.nature.com/2F8lQ2v

NaturePortfolio's tweet image. An RNA vaccine candidate for SARS-CoV-2, BNT162b1, is shown to induce a robust immune response in healthy adults aged 18–55 years in an interim report of a phase 1/2 clinical trial published in Nature. go.nature.com/2F8lQ2v

Loading...

Something went wrong.


Something went wrong.